Actively Recruiting
Cell-free DNA in Acute Stroke
Led by University Hospital, Basel, Switzerland · Updated on 2025-04-15
200
Participants Needed
1
Research Sites
74 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Cell-free DNA (cfDNA) is an important pro-inflammatory and prothrombotic mediator. With this study the investigators aim to gain new insights into the role of cfDNA in stroke and to perform a combined analysis of cfDNA in the hyperacute phase of the disease using blood and thrombus analyses. The main objectives are to analyse cfDNA in different stroke etiologies, to investigate the relationship between cfDNA and important procedural factors such as secondary embolisation and reperfusion outcomes, to analyse the correlation between blood and thrombus content of cfDNA and to investigate the specific source of cfDNA in distinct stroke subtypes.
CONDITIONS
Official Title
Cell-free DNA in Acute Stroke
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Acute ischemic stroke due to large vessel occlusion (LVO) requiring mechanical thrombectomy confirmed by CT or MRI scan
- 18 years of age or older
You will not qualify if you...
- Receiving immunological therapies at the time of enrollment
- Having immunological diseases
- Having systemic infections at the time of admission
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
University Hospital Basel
Basel, Switzerland, 4031
Actively Recruiting
Research Team
G
Gerrit Grosse, PD Dr. Dr.
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here